Cells expressing the CD133 (AC133, Prominin-1) marker are generally known as primitive hematopoietic stem and progenitor cells (HSC and HPC). While cells expressing the CD133 marker are usually undifferentiated embryonic stem cell lines, this cell type is usually harvested from bone marrow and cord blood but can be also found in multiple locations including the liver, muscle, prostate, kidney, and neural tissue. CD133 stem cells appear to be ancestral to the CD34+ stem cell line due to their ability to differentiate into CD34+ cells and also their higher level of proliferation activity.
Capable of a high level of proliferation and a wide range of differentiation, transplantation of CD133+ cell lines has been shown to not only induced multilineage human hematopoiesis through the CD34+ lineage, but also induce regeneration of cell lines in vitro in multiple locations by differentiating into endothelial cells, neural cells, hepatocytes, osteoblasts, and myocytes, with the list of tissue types this cell can differentiate into gradually increasing.
CD133+ stem cells are isolated using positive immunomagnetic cell separation procedures from a mobilized leukapheresis collection.
Use fresh mobilized CD133+ stem cells immediately upon receipt. Be sure to remove HypoThermosol® prior to use. If not used immediately, temporarily store cells at 0-4°C or freeze for long-term storage.
For cryopreserved mobilized CD133+ stem cells, either prepare cells for long-term storage in Liquid Nitrogen vapor phase or thaw for use. Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately.
Testing: Donors are tested for HBV, HCV, HIV, HTLV, WNV, Trypanasoma cruzi, and Syphilis.